<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869293</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200879</org_study_id>
    <secondary_id>IDRCB 2020-A02052-37</secondary_id>
    <nct_id>NCT04869293</nct_id>
  </id_info>
  <brief_title>Lithotripsy and Analgesia With 3D Hypnosis Mask</brief_title>
  <acronym>LAHMA</acronym>
  <official_title>Assessment of Analgesia Through Hypnosis With 3D Virtual Reality During Extra-corporeal Lithotripsy (LAHMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GAMIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Healthy Mind</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomised trial of hypnosis with 3D virtual reality headset (intervention&#xD;
      group) versus control group with no hypnosis and no virtual reality headset to compare&#xD;
      remifentanil consumption during shock wave lithotripsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is for patients undergoing shock wave lithotripsy in outpatient surgery unit.&#xD;
&#xD;
      It is proposed that using hypnosis with 3D virtual reality headset will reduce the&#xD;
      requirements for intravenous remifentanil in a randomised controlled trial of one hundred and&#xD;
      six patients.&#xD;
&#xD;
      Remifentanil is an opioid commonly used for lithotripsy. Shock wave lithotripsy is a commonly&#xD;
      performed procedure associated with moderate pain and anxiety, in outpatient surgery unit.&#xD;
      Opioids can cause unfavourable side-effects, most notably respiratory depression, sedation,&#xD;
      nausea and vomiting&#xD;
&#xD;
      It is expected that by using 3D virtual reality to reduce pain and anxiety, there will be a&#xD;
      reduced requirement for intravenous remifentanil.&#xD;
&#xD;
      The study will measure the dose of remifentanil required by patients randomised to receive&#xD;
      either hypnosis with 3D virtual reality headset (intervention) or no hypnosis and no 3D&#xD;
      virtual reality headset (control group).&#xD;
&#xD;
      Patients will be followed up prior to hospital discharge to assess their remifentanil use and&#xD;
      pain, anxiety, comfort and their satisfaction with 3D virtual reality headset.&#xD;
&#xD;
      This new device is a non-pharmacological adjunct and can reduce pain intensity during&#xD;
      procedure, reduce opioid use and length of stay in hospital and improve the patient&#xD;
      experience whilst potentially reducing complications of intravenous opioid.&#xD;
&#xD;
      This study findings will be of interest for patients involved in surgery or investigative&#xD;
      procedures normally carried out with intravenous opioids or sedation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remifentanil use</measure>
    <time_frame>Hour 1</time_frame>
    <description>Remifentanil consumption (microgram) during shock wave lithotripsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal level of pain during shock wave lithotripsy</measure>
    <time_frame>Hour 1</time_frame>
    <description>Use of analogical visual pain self-assessment at the end of the shock wave lithotripsy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Renal Calculi</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>3D virtual reality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Hypnosis 3D virtual reality headset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hypnosis 3D virtual reality headset</intervention_name>
    <description>3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.</description>
    <arm_group_label>3D virtual reality</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Shock wave lithotripsy and outpatient surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Deafness, Blindness&#xD;
&#xD;
          -  Schizophrenia, Hallucinations&#xD;
&#xD;
          -  No french-speaking&#xD;
&#xD;
          -  Autistic&#xD;
&#xD;
          -  Motion sickness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darless Clausse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital européen Geroges-Pompidou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darless Clausse, MD</last_name>
    <phone>331 56 09 54 11</phone>
    <email>darless.clausse@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha Nohilé</last_name>
    <phone>331 56 09 59 82</phone>
    <email>natacha.nohile@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris, Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Darless Clausse, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Darless CLAUSSE, MD</last_name>
      <phone>331 56 09 54 11</phone>
      <email>darless.clausse@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Eijlers R, Utens EMWJ, Staals LM, de Nijs PFA, Berghmans JM, Wijnen RMH, Hillegers MHJ, Dierckx B, Legerstee JS. Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. Anesth Analg. 2019 Nov;129(5):1344-1353. doi: 10.1213/ANE.0000000000004165.</citation>
    <PMID>31136330</PMID>
  </reference>
  <reference>
    <citation>Scapin S, Echevarría-Guanilo ME, Boeira Fuculo Junior PR, Gonçalves N, Rocha PK, Coimbra R. Virtual Reality in the treatment of burn patients: A systematic review. Burns. 2018 Sep;44(6):1403-1416. doi: 10.1016/j.burns.2017.11.002. Epub 2018 Feb 1.</citation>
    <PMID>29395400</PMID>
  </reference>
  <reference>
    <citation>Chan E, Foster S, Sambell R, Leong P. Clinical efficacy of virtual reality for acute procedural pain management: A systematic review and meta-analysis. PLoS One. 2018 Jul 27;13(7):e0200987. doi: 10.1371/journal.pone.0200987. eCollection 2018.</citation>
    <PMID>30052655</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapeutic virtual reality</keyword>
  <keyword>hypnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Two years after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. Collaboration will be fostered.&#xD;
Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and IP team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement.&#xD;
Processing of shared data must comply with European General Data Protection Regulation (GDPR).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

